Momenta Pharmaceuticals, Inc. (MNTA)
| Market Cap | 6.24B |
| Revenue (ttm) | 30.07M |
| Net Income (ttm) | -227.83M |
| Shares Out | 117.87M |
| EPS (ttm) | -2.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Oct 1, 2020 |
| Last Price | $52.48 |
| Previous Close | $52.48 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 52.46 - 52.53 |
| Day's Volume | 0 |
| 52-Week Range | 12.21 - 52.53 |
News
CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing nove...
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.
CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing...
Momenta (MNTA) reported earnings 30 days ago. What's next for the stock?
New York, New York--(Newsfile Corp. - August 31, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orde...
Momenta Pharmaceuticals stock was thrust into the financial headlines and might look tempting, but don't forget that price is king. The post Buyout Excitement Is Already Priced Into Momenta Ph...
Johnson & Johnson has increased its dividend for 58 years in a row (a dividend king) and presently has a yield of 2.7%, which is above average.
Johnson & Johnson to enroll 60,000 participants in the late-stage trial for its COVID-19 vaccine.
Johnson & Johnson (NYSE: JNJ) is borrowing $7.5 billion in bonds to help fund its purchase of Momenta Pharmaceuticals, Inc (NASDAQ: MNTA) as a series of companies tap the debt market to financ...
New York, New York--(Newsfile Corp. - August 20, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Momenta Pharmaceuticals, Inc.
J&J (JNJ) offers to buy Momenta, which focuses on the development of novel drugs to treat rare, immune-mediated disorders.
The stock price of Momenta Pharmaceuticals, a pharmaceutical company best known for its immunology therapies, has rallied around 26% over recent weeks (vs. about a 50% gain in the S&P 500) to ...
NEW YORK, Aug. 19, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Momenta Pharmaceuticals, Inc.
Momenta Pharmaceuticals (MNTA) news for Wednesday includes a deal with Johnson & Johnson (JNJ) sending MNTA stock rocketing higher.
NEW YORK, Aug. 19, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...
The company is paying a big premium to expand its autoimmune disease treatment footprint.
Johnson & Johnson will buy Momenta Pharmaceuticals for $6.5 billion to broaden its reach in treating autoimmune and rare diseases. The post Johnson & Johnson To Acquire Momenta Pharmaceutical...
SAN DIEGO, Aug. 19, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Momenta Pharmaceuticals, Inc.
Johnson & Johnson to buy Momenta for about $6.5 billion
Johnson & Johnson said on Wednesday it would buy Momenta Pharmaceuticals for about $6.5 billion in cash to expand into the area of autoimmune disease treatments.
Shares of Momenta Pharmaceuticals Inc. MNTA, +5.04% rocketed 69% into record territory in premarket trading Wednesday, after the biotechnology company announced an agreement to be acquired by ...
Johnson & Johnson said on Wednesday it would buy Momenta Pharmaceuticals Inc for about $6.5 billion in cash to expand into the area of autoimmune disease treatments.
CAMBRIDGE, Mass., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing no...
NEW BRUNSWICK, N.J., Aug. 19, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig Wheeler on Q2 2020 Results - Earnings Call Transcript
Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig Wheeler on Q2 2020 Results - Earnings Call Transcript
Momenta (MNTA) delivered earnings and revenue surprises of -14.29% and 13.15%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) rose 1% after the company reported Q2 results.
-- Interim Phase 2 Vivacity-MG results met primary endpoints, demonstrating nipocalimab was well-tolerated and achieved rapid and durable responses with significant correlation (p
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to...
Momenta (MNTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that its novel drug candidate, nipocalimab, has received rare pediatric dis...
Top Ranked Momentum Stocks to Buy for July 6th
Momenta (MNTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Despite market's roller-coaster ride, a handful of momentum stocks with a favorable Zacks Rank have provided double-digit returns so far in June.
As of late, it has definitely been a great time to be an investor in Momenta Pharmaceuticals, Inc. (MNTA).
Momenta (MNTA) stock up on the announcement of positive data from a mid-stage study on nipocalimab for the indication of gMG.
Positive phase 2 clinical trial data puts the biotech's lead drug candidate on a good path forward.
- Trial met primary endpoint with a strong relationship between Immunoglobulin G (IgG) reduction and MG-ADL clinical benefit (p
Momenta (MNTA) reported earnings 30 days ago. What's next for the stock?
Here’s why this drugmaker targeting autoimmune conditions and rare diseases is a solid buy.
Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig Wheeler on Q1 2020 Results - Earnings Call Transcript
Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig Wheeler on Q1 2020 Results - Earnings Call Transcript
Momenta (MNTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics...
Momenta (MNTA) reported earnings 30 days ago. What's next for the stock?
An overall market rebound and a presidential press conference carried several biotech and pharmaceutical stocks markedly higher.
Investors ran back into the stock after one of the worst weeks in market history. Will it prove sustainable?
Momenta (MNTA) reports mixed Q4 results, with a wider-than-expected loss and revenues beating the same.
Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig Wheeler on Q4 2019 Results - Earnings Call Transcript
Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig Wheeler on Q4 2019 Results - Earnings Call Transcript
About MNTA
Momenta Pharmaceuticals, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and ... [Read more...]
| Industry Drug Manufacturers—Specialty & Generic | IPO Date Jun 22, 2004 |
| CEO Craig A. Wheeler | Employees 118 |
| Stock Exchange NASDAQ | Ticker Symbol MNTA |
Financial Performance
In 2019, MNTA's revenue was $23.87 million, a decrease of -68.42% compared to the previous year's $75.59 million. Losses were -$290.06 million, 64.7% more than in 2018.